Literature DB >> 26103532

Cytokine-dependent bidirectional connection between impaired social behavior and susceptibility to seizures associated with maternal immune activation in mice.

James Washington1, Udaya Kumar1, Jesus-Servando Medel-Matus1, Don Shin1, Raman Sankar2, Andrey Mazarati3.   

Abstract

Maternal immune activation (MIA) results in the development of autism in the offspring via hyperactivation of IL-6 signaling. Furthermore, experimental studies showed that the MIA-associated activation of interleukin-1β (IL-1β) concurrently with IL-6 increases the rate and the severity of hippocampal kindling in mice, thus, offering an explanation for autism-epilepsy comorbidity. We examined whether epileptic phenotype triggered by prenatal exposure to IL-6 and IL-1β combination is restricted to kindling or whether it is reproducible in another model of epilepsy, whereby spontaneous seizures develop following kainic acid (KA)-induced status epilepticus. We also examined whether in mice prenatally exposed to IL-6 and IL-6+IL-1β, the presence of spontaneous seizures would exacerbate autism-like features. Between days 12 and 16 of pregnancy, C57BL/6J mice received daily injections of IL-6, IL-1β, or IL-6+IL-1β combination. At postnatal day 40, male offspring were examined for the presence of social behavioral deficit, and status epilepticus was induced by intrahippocampal KA injection. After 6weeks of monitoring for spontaneous seizures, sociability was tested again. Both IL-6 and IL-6+IL-1β offspring presented with social behavioral deficit. Prenatal exposure to IL-6 alleviated, while such exposure to IL-6+IL-1β exacerbated, the severity of KA-induced epilepsy. Increased severity of epilepsy in the IL-6+IL-1β mice correlated with the improvement of autism-like behavior. We conclude that complex and not necessarily agonistic relationships exist between epileptic and autism-like phenotypes in an animal model of MIA coupled with KA-induced epilepsy and that the nature of these relationships depends on components of MIA involved.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autism; Comorbidity; Cytokines; Epilepsy; Interleukin-1β; Interleukin-6; Maternal immune activation

Mesh:

Substances:

Year:  2015        PMID: 26103532      PMCID: PMC4562803          DOI: 10.1016/j.yebeh.2015.05.040

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  40 in total

Review 1.  The epidemiology of autism: a review.

Authors:  E Fombonne
Journal:  Psychol Med       Date:  1999-07       Impact factor: 7.723

2.  Maternal immune activation yields offspring displaying mouse versions of the three core symptoms of autism.

Authors:  Natalia V Malkova; Collin Z Yu; Elaine Y Hsiao; Marlyn J Moore; Paul H Patterson
Journal:  Brain Behav Immun       Date:  2012-01-30       Impact factor: 7.217

3.  Autism after infection, febrile episodes, and antibiotic use during pregnancy: an exploratory study.

Authors:  Hjördis Ósk Atladóttir; Tine Brink Henriksen; Diana E Schendel; Erik T Parner
Journal:  Pediatrics       Date:  2012-11-12       Impact factor: 7.124

4.  Principles and pitfalls in the analysis of prenatal treatment effects in multiparous species.

Authors:  R R Holson; B Pearce
Journal:  Neurotoxicol Teratol       Date:  1992 May-Jun       Impact factor: 3.763

5.  Maternal immune activation promotes hippocampal kindling epileptogenesis in mice.

Authors:  Eduardo Pineda; Don Shin; Su Jeong You; Stéphane Auvin; Raman Sankar; Andréy Mazarati
Journal:  Ann Neurol       Date:  2013-08-06       Impact factor: 10.422

6.  Maternal immune activation causes age- and region-specific changes in brain cytokines in offspring throughout development.

Authors:  Paula A Garay; Elaine Y Hsiao; Paul H Patterson; A K McAllister
Journal:  Brain Behav Immun       Date:  2012-07-25       Impact factor: 7.217

7.  Blood plasma inflammation markers during epileptogenesis in post-status epilepticus rat model for temporal lobe epilepsy.

Authors:  Linda Holtman; Erwin A van Vliet; Eleonora Aronica; Diana Wouters; Wytse J Wadman; Jan A Gorter
Journal:  Epilepsia       Date:  2013-02-08       Impact factor: 5.864

8.  Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling.

Authors:  Csaba Földy; Robert C Malenka; Thomas C Südhof
Journal:  Neuron       Date:  2013-04-11       Impact factor: 17.173

9.  Improving basic and translational science by accounting for litter-to-litter variation in animal models.

Authors:  Stanley E Lazic; Laurent Essioux
Journal:  BMC Neurosci       Date:  2013-03-22       Impact factor: 3.288

10.  Effect of topiramate on interleukin 6 expression in the hippocampus of amygdala-kindled epileptic rats.

Authors:  Fei Ye; Xu-Qin Chen; Guan-Shui Bao; Yin Hua; Zhe-Dong Wang; Yi-Chuan Bao
Journal:  Exp Ther Med       Date:  2013-11-08       Impact factor: 2.447

View more
  4 in total

1.  Genetic backgrounds have unique seizure response profiles and behavioral outcomes following convulsant administration.

Authors:  Nycole Ashley Copping; Anna Adhikari; Stela Pavlova Petkova; Jill Lynn Silverman
Journal:  Epilepsy Behav       Date:  2019-11-04       Impact factor: 2.937

Review 2.  Influence of Prenatal Drug Exposure, Maternal Inflammation, and Parental Aging on the Development of Autism Spectrum Disorder.

Authors:  Atsushi Sato; Hiroko Kotajima-Murakami; Miho Tanaka; Yoshihisa Katoh; Kazutaka Ikeda
Journal:  Front Psychiatry       Date:  2022-02-09       Impact factor: 4.157

3.  Under or Absent Reporting of Light Stimuli in Testing of Anxiety-Like Behaviors in Rodents: The Need for Standardization.

Authors:  Lorenz S Neuwirth; Michael T Verrengia; Zachary I Harikinish-Murrary; Jessica E Orens; Oscar E Lopez
Journal:  Front Mol Neurosci       Date:  2022-08-17       Impact factor: 6.261

Review 4.  Neuroinflammation: A Signature or a Cause of Epilepsy?

Authors:  Enrico Pracucci; Vinoshene Pillai; Didi Lamers; Riccardo Parra; Silvia Landi
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.